Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug:226:161-173.
doi: 10.1016/j.ahj.2020.04.010. Epub 2020 Apr 20.

A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data

Affiliations

A multicenter trial of a shared DECision Support Intervention for Patients offered implantable Cardioverter-DEfibrillators: DECIDE-ICD rationale, design, Medicare changes, and pilot data

Bryan C Wallace et al. Am Heart J. 2020 Aug.

Abstract

Shared decision making (SDM) facilitates delivery of medical therapies that are in alignment with patients' goals and values. Medicare national coverage decision for several interventions now includes SDM mandates, but few have been evaluated in nationwide studies. Based upon a detailed needs assessment with diverse stakeholders, we developed pamphlet and video patient decision aids (PtDAs) for implantable cardioverter/defibrillator (ICD) implantation, ICD replacement, and cardiac resynchronization therapy with defibrillation to help patients contemplate, forecast, and deliberate their options. These PtDAs are the foundation of the Multicenter Trial of a Shared Decision Support Intervention for Patients Offered Implantable Cardioverter-Defibrillators (DECIDE-ICD), a multicenter, randomized trial sponsored by the National Heart, Lung, and Blood Institute aimed at understanding the effectiveness and implementation of an SDM support intervention for patients considering ICDs. Finalization of a Medicare coverage decision mandating the inclusion of SDM for new ICD implantation occurred shortly after trial initiation, raising novel practical and statistical considerations for evaluating study end points. METHODS/DESIGN: A stepped-wedge randomized controlled trial was designed, guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) planning and evaluation framework using an effectiveness-implementation hybrid type II design. Six electrophysiology programs from across the United States will participate. The primary effectiveness outcome is decision quality (defined by knowledge and values-treatment concordance). Patients with heart failure who are clinically eligible for an ICD are eligible for the study. Target enrollment is 900 participants. DISCUSSION: Study findings will provide a foundation for implementing decision support interventions, including PtDAs, with patients who have chronic progressive illness and are facing decisions involving invasive, preference-sensitive therapy options.

PubMed Disclaimer

Conflict of interest statement

Disclosures/conflict of interest

Dr. Allen receives grant funding from American Heart Association, National Institutes of Health, and the Patient Centered Outcomes Research group; and consulting fees from ACI Clinical, Amgen/Cytokinetics, Boston Scientific, and Novartis.

Dr. Knoepke is supported by a career development award from the American Heart Association (18CDA34110026, Knoepke).

Dr. Tzou would like to disclose consulting, speaker honoraria, and grant support for Abbott, Boston Scientific, and Biosense Webster; consulting and speaker honoraria for Biotronik, consulting for BioSig, and speaker honoraria for Medtronic.

Dr. Gupta receives fellowship support and speaking honoraria from Boston Scientific and Medtronic. In addition, Dr. Gupta has research grants from Abbott/St. Jude Medical and Bristol-Meyers-Squibb.

Dr. Peterson receives grant funding from the National Institutes of Health and Astra Zeneca.

Dr. Matlock has received funding from the National Institutes of Health and the Patient Centered Outcomes Research Institute.

Mr. Wallace, Dr. Glasgow, Dr. Lewis, Dr. Fairclough, Ms. Helmkamp, Ms. Fitzgerald, Dr. Kramer, Dr. Varosy, Dr. Mandrola, and Dr. Brancato all have no significant disclosures or conflicts of interest.

Figures

Figure I:
Figure I:
PRECIS-2 Diagram outlining pragmatism of proposed trial in 9 domains, compared to usual clinical care.

References

    1. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009--a World Society of Arrhythmia's project. Pacing and clinical electrophysiology : PACE 2011;34:1013–27. - PubMed
    1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England journal of medicine 2005;352:225–37. - PubMed
    1. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.[see comment]. New England Journal of Medicine 350(21):2140–50, 2004. - PubMed
    1. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. The New England journal of medicine 2002;346:877–83. - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–239. - PubMed

Publication types